Across TCGA pan-cancer cohorts, APCDD1L Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated APCDD1L data layer compared with 27 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher APCDD1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APCDD1L expression acts as an unfavorable survival marker.

LIHC, HNSC, and LUAD are the cancer types where APCDD1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.094	0.783	<.001	24	view →
HNSC	OS	Median	III,IV	0.115	0.746	<.001	24	view →
LUAD	DFS	Median	II,III,IV	0.178	0.721	.008	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: APCDD1L tumor-vs-normal RNA expression · all APCDD1L data types